Kerri Fitzgerald

DocwireNews

Since its approval in January 2018, Prolia&reg; (denosumab) has seen an increase in use in patients with <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/bcma-car-t-therapy-for-multiple-myeloma-induces-100-response/">multiple myeloma</a> (MM) compared with Reclast&reg; (zoledronic acid), despite having a higher price tag ($2,500 vs. $50 per dose, respectively), according to research published in JAMA Oncology.The study found that in 15 months following its approval, denosumab was being used in 40% of <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/does-revlimid-warrant-a-change-in-standard-of-care-for-smoldering-multiple-myeloma/">patients with MM</a>. Zoledronic acid is a bisphosphonate, and denosumab has a novel mechanism of action that involves receptor activator of nuclear factor kappa-&Beta; ligand.A 2017 head-to-head comparison of the bone-modifying agents in more than 1,000 patients with MM found denosumab and zoledronic acid were noninferior in terms of time to skeletal-related events and survival. Denosumab reduced the risk of renal adverse events, thus the recent article noted that denosumab may be more beneficial in some, but not all, patients with kidney dysfunction.<h2>Increased use of denosumab between 2017 and 2019</h2>In the recent study, the authors used Medicare fee-for-service claims data from January 1, 2017, to March 31, 2019, to identify 15,872 patients with MM (mean age, 72.7 years) who had a total of 329,595 person-months of follow-up. The overall rate of denosumab use prior to its approval was 3.8 doses per 1,000 person-months compared with 84.1 doses per 1,000 person-months following its approval.Of the total number of bone-modifying agent doses, the percentage of denosumab doses increased from 0.1% throughout 2017 to 38.1% in March 2019.The adjusted incidence rate ratio of denosumab use was 36.0 for patients without renal dysfunction and 17.9 for those with renal dysfunction.The study did not assess the reason for this uptake.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

This Multiple Myeloma Drug Is Gaining Traction, Despite Costs

Oncology

Since its approval in January 2018, Prolia® (denosumab) has seen an increase in use in patients with multiple myeloma (MM) compared with Reclast® (zoledronic acid), despite ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe